Neutropenia Associated With B Cell–Depleting Therapies in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
This study is comprehensive and reflects a large cohort, examining incidence rates of neutropenia with BCDT in MS and NMOSD. Overall, neutropenia was still rare, occurring at a rate of 0.66 per 100 person-years, and infections were associated triggers in some patients. Yet, of relevance to clinicians, neutropenia was not benign: half required hospitalization and 35% experienced recurrence, which is higher than what was reported in clinical trials.
Authors
- Samuel J. Pleasure (ORCID: https://orcid.org/0000-0001-8599-1613)
- Michael R. Wilson (ORCID: https://orcid.org/0000-0002-8705-5084)
- Scott S. Zamvil (ORCID: https://orcid.org/0000-0003-2720-9915)
- Greer Waldrop (ORCID: https://orcid.org/0000-0001-6408-2330)
- Jeffrey Marc Gelfand (ORCID: https://orcid.org/0000-0002-5121-3319)
- Shane T. Poole (ORCID: https://orcid.org/0000-0002-3203-151X)
- Riley M. Bove (ORCID: https://orcid.org/0000-0002-2034-8800)
- Chu‐Yueh Guo (ORCID: https://orcid.org/0000-0002-5730-7770)
- Nikki Sisodia (ORCID: https://orcid.org/0009-0006-7270-595X)
Institutions
- University of California, San Francisco (US)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1212/nxi.0000000000200430
- Citations
- 5
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 7.36